• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
CONCLUSIONS: There is not enough evidence for or against NOACs or for high-intensity VKA compared to the standard VKA therapy in the secondary prevention of thrombosis in people with APS. There is some evidence of harm for high-intensity VKA regarding minor and any bleeding. The evidence was also not sufficient to show benefit or harm for VKA plus antiplatelet agent or dual antiplatelet therapy compared to a single antiplatelet drug. Future studies should be adequately powered, with proper adherence to treatment, in order to evaluate the effects of anticoagulants, antiplatelets, or both, for secondary thrombosis prevention...
Source: Cochrane Database of Systematic Reviews - October 2, 2017 Category: General Medicine Authors: Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A Tags: Cochrane Database Syst Rev Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fish Oil and Vitamin D Supplements May Not Help Prevent Heart Attacks and Cancer, Study Says
There’s good evidence that fish oil supplements may lower the risk of second heart events — like a heart attack or stroke — in people with heart disease, but few rigorous studies have investigated whether the supplement can help people to lower their risk of having a heart event in the first place. And while some data suggests that people with lower levels of vitamin D tend to have higher rates of heart disease and cancer, the evidence isn’t solid. Now, a new study published in the New England Journal of Medicine and presented at the annual meeting of the American Heart Association offers more findi...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs Source Type: news

Evidence That Increasing Serum 25(OH)D Concentrations to 30 ng/mL in the Kingdom of Saudi Arabia and the United Arab Emirates Could Greatly Improve Health Outcomes
Biomedicines. 2023 Mar 23;11(4):994. doi: 10.3390/biomedicines11040994.ABSTRACTAccumulating evidence supports the potential protective effects of vitamin D against chronic diseases such as Alzheimer's disease, autoimmune diseases, cancers, cardiovascular disease (ischaemic heart disease and stroke), type 2 diabetes, hypertension, chronic kidney disease, stroke, and infectious diseases such as acute respiratory tract diseases, COVID-19, influenza, and pneumonia, as well as adverse pregnancy outcomes. The respective evidence is based on ecological and observational studies, randomized controlled trials, mechanistic studies, ...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: William B Grant Fatme Al Anouti Barbara J Boucher Hana M A Fakhoury Meis Moukayed Stefan Pilz Nasser M Al-Daghri Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

E-061 Moyamoya syndrome patients have low vitamin D
ConclusionOur data indicate a large proportion of moyamoya syndrome patients are deficient in vitamin D, which we hypothesize contributes to pathological severity. Future studies incorporating vitamin D supplementation may act as a novel intervention for this patient population that currently has few treatment options.Disclosures J. Fraser: None. L. Whitnel: None. J. Roberts: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Fraser, J., Whitnel, L., Roberts, J. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Serum vitamin D deficiency and its association with systemic disease in exfoliation syndrome.
Conclusions: Although vitamin D levels were similar between XFS and control subjects, the levels were found to be decreased in both groups. Patients with XFS had a significantly higher prevalence of cerebrovascular and cardiovascular disease as compared to controls independent of their 
serum 25(OH) D levels. Low vitamin D level does not appear to be linked to XFS in the studied population. PMID: 23564611 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - April 8, 2013 Category: Opthalmology Authors: Kocabeyoglu S, Mocan MC, Irkec M, Pinar A, Bozkurt B, Orhan M Tags: Eur J Ophthalmol Source Type: research

Vitamin D Deficiency Is As Dangerous As Smoking
The advice you’re getting from your doctor, the TV and even the Surgeon General is so wrong, it’s scary. They’re all busy telling you to stay out of the sun. But Swedish researchers recently discovered that nonsmokers who avoid the sun have a life expectancy similar to smokers who spend a lot of time in the sun. Staying out of the sun is as dangerous as smoking.1 It doesn’t surprise me. I tell all my patients sunlight exposure is essential to our health because it is the best source of vitamin D… possibly the most important nutrient we know of. Mainstream medicine still doesn’t recognize th...
Source: Al Sears, MD Natural Remedies - May 19, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news